Home » Healthcare Professionals » Publications

Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2

Emily Y. Chew, M.D., Mark Gillies, M.D., Ph.D., Glenn J. Jaffe, M.D., Alain Gaudric, M.D., Cathy Egan, M.D., Ian Constable, A.O., Traci Clemons, Ph.D., Thomas Aaberg, Jr. M.D., Debora C. Manning, M.P.H, Thomas C. Hohman, Ph.D., Alan Bird, M.D., and martin Friedlander, M.D., Ph.D., for the MacTel CNTF NTMT-03 Research Investigators. Published July 22, 2025, NEJM Evid 2025;4(8), DOI: 10.1056/EVIDoa2400481, VOL. 4 NO.8

Long-Term Durability of Ciliary Neurotrophic Factor-Releasing Revakinagene Taroretcel-lwey in Individuals With Retinal Degenerative Disorders

Konrad Kauper, Arne Nystuen, Lisa Orecchio, Eugene Gonzalez-Lopez, Alice Lee, Jacque L. Duncan, Jay M. Stewart, Thomas Aaberg, Jr. M.D., Invest Ophthalmol Vis Sci. 2025 August 1;66(11):3. doi: 10:1167/iovs.66.11.3. PMID: 4075774, PMCID: PMC12327535

Neuroprotective properties of ciliary neurotrophic factor in the retina for the treatment of macular telangiectasia type 2

Arne Nystuen, Eugene Gonzalez-Lopez, Konrad A. Kauper, Kevin Eade, Thomas M. Aaberg, Jr., M.D., Cytokine Growth Factor Rev. 2025 Aug:84:12-19. doi: 10.1016/j.cytogfr.2025.06.005. Epub 2025 Jun 18. PMID: 40562629